You can watch SVA and buy or sell other stocks, options, ETFs, and crypto commission-free!
Sinovac Biotech, Ltd. Ordinary Shares, also called Sinovac Biotech, is a holding company, which engages in the research, development, manufacture, and commercialization of vaccines that protect against human infectious diseases. Read More Its product portfolio includes vaccines against enterovirus71, or EV71, hepatitis A and B, seasonal influenza, H5N1 pandemic influenza, H1N1 influenza, and mumps. The company was founded in 1993 and is headquartered in Beijing, China.
52 Week High
52 Week Low
Associated PressMar 11
Sinovac’s Poison Pill Attempt Stopped by Court Orders
BOSTON and BEIJING, March 11, 2019 (GLOBE NEWSWIRE) -- In a court order dated March 6, 2019, the Honorable J. Travis Laster of the Delaware Court of Chancery ordered Sinovac Biotech Ltd.
Associated PressMar 8
Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
BEIJING--(BUSINESS WIRE)--Mar 8, 2019--Sinovac Biotech Ltd. (NASDAQ:SVA) (“Sinovac” or the “Company”), a leading provider of biopharmaceutical products in China, today issued an update on the Exchange of Rights for Common and Series B Preferred Shares announced February 22, 2019. On February 22, 2019, as announced by press release, the Sinovac Board of Directors effectuated an Exchange of Rights held by certain Sinovac’s shareholders for a combination of approximately 27.8 million Common Shares and approxi...